Saturday, October 31, 2026

Moderna Stock Over 6% Down So Far Today

ViaNews Editorial Team

December 22, 2020

Moderna Stock Over 6% Down So Far Today

Shares of Moderna slid 6.67% to $129.07 at 11:11 EST on Tuesday, after two consecutive sessions in a row of losses. The Nasdaq Stock Market is jumping 0.46% to $12,800.90, after two consecutive sessions in a row of losses. This seems, as yet, a somewhat positive trend trading session today.

Moderna's last close was $138.30, 38.30% below its 52-week high of $178.50.

Moderna's Sales

Moderna's sales growth is 1841.7% for the present quarter and 19117.5% for the next. The company's growth estimates for the ongoing quarter is a negative 2.7% and positive 660% for the next.

Moderna's Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's Stock Yearly Top and Bottom Value

Moderna's stock is valued at $129.07 at 11:11 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna's Moving Average

Moderna's value is way above its 50-day moving average of $116.47 and way higher than its 200-day moving average of $80.87.

Previous days news about Moderna

Moderna shot cleared in U.S., boosting immunization effort. According to Bloomberg Quint on Sat Dec 19, "United Parcel Service Inc., under an agreement with McKesson, will begin to deliver Moderna's vaccine, the cargo giant said in a statement Friday.", ""I am proud of what the Moderna team has achieved in collaboration with our partners," Stéphane Bancel, the company's chief executive officer, said. "

Moderna, exxon, Alphabet, Amazon: stocks that defined the week. According to The Wall Street Journal on Sat Dec 19, "U.S. health regulators late Friday permitted use of Moderna's Covid-19 vaccine, the second shot to get the green light to help end the pandemic. ", "Moderna shares rose 5.1% Thursday when an advisory panel cleared the way for Friday night's authorization."

Statement on the U.S. authorization of the Moderna Covid-19 vaccine. According to Business Insider on Sat Dec 19, "OTTAWA, ON, Dec. 18, 2020 /CNW/ -Health Canada is aware that the U.S. Food and Drug Administration has issued an emergency use authorization for a COVID-19 vaccine manufactured by Moderna.", "Health Canada has been reviewing Moderna's vaccine since it was submitted on October 12, 2020, and is expediting the review of COVID-19 vaccines. "

Moderna to begin delivery; london lockdown ordered: virus update. According to Bloomberg Quint on Sat Dec 19, "The Food and Drug Administration gave emergency-use approval to the Moderna vaccine on Friday night, a week after approving the Pfizer Inc./BioNTech SE shot.", "That allocation will bolster the 55.8 million doses that it will receive through a European Union plan, with a further 50.5 million doses of the Moderna Inc. due from the EU. "

Philippines to start vaccine talks with Moderna by year-end: CNN. According to Bloomberg Quint on Mon Dec 21, "The Philippines will start talks with Moderna Inc. on or before Dec. 30 to secure supply of the company's coronavirus vaccine, Foreign Affairs Secretary Teodoro Locsin said Monday.", ""Moderna is interested in giving an allocation," he said in a live-streamed interview with CNN Philippines, citing Philippine ambassador to the U.S. Jose Manuel Romualdez."

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com